A single intratumoral injection of a fiber-mutant adenoviral vector encoding interleukin 12 induces remarkable anti-tumor and anti-metastatic activity in mice with Meth-A fibrosarcoma

被引:18
作者
Gao, JQ
Sugita, T
Kanagawa, N
Iida, K
Eto, Y
Motomura, Y
Mizuguchi, H
Tsutsumi, Y
Hayakawa, T
Mayumi, T
Nakagawa, S
机构
[1] Osaka Univ, Grad Sch Pharmaceut Sci, Dept Biopharmaceut, Suita, Osaka 5650871, Japan
[2] Zhejiang Univ, Coll Pharmaceut Sci, Dept Pharmaceut, Hangzhou 310031, Zhejiang, Peoples R China
[3] Natl Inst Hlth Sci, Osaka Branch, Fundamental Res Labs Dev Med, Chuo Ku, Osaka 5400006, Japan
[4] Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan
[5] Kobe Gakuin Univ, Grad Sch Pharmaceut Sci, Dept Cell Therapeut, Nishi Ku, Kobe, Hyogo 6512180, Japan
关键词
interleukin; 12; Meth-A fibrosarcoma; recombinant adenoviral vector; anti-tumor; anti-metastasis; intratumoral administration; IL-12; insensitive;
D O I
10.1016/j.bbrc.2005.01.061
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Cytokine-encoding viral vectors are considered to be promising in cancer gene immunotherapy. Interleukin 12 (IL-12) has been used widely for anti-tumor treatment, but the administration route and tumor characteristics strongly influence therapeutic efficiency. Meth-A fibrosarcoma has been demonstrated to be insensitive to IL-12 treatment via systemic administration. In the present study, we developed an IL-12-encoding fiber-mutant adenoviral vector (AdRGD-IL-12) that showed enhanced gene transfection efficiency in Meth-A tumor cells, and the production of IL-12 p70 in the culture supernatant from transfected cells was confirmed by ELISA. In therapeutic experiments, a single low-dose (2 X 107 plaque-forming units) intraturnoral injection of AdRGD-IL-12 elicited pronounced anti-tumor activity and notably prolonged the survival of Meth-A fibrosarcoma-bearing mice. Immunohistochemical staining revealed that the IL-12 vector induced the accumulation of T cells in tumor tissue. Furthermore, intraturnoral administration of the vector induced an anti-metastasis effect as well as long-term specific immunity against syngeneic tumor challenge. (C) 2005 Elsevier Inc. All rights reserved.
引用
收藏
页码:1043 / 1050
页数:8
相关论文
共 39 条
[1]  
Akporiaye ET, 1999, CURR OPIN MOL THER, V1, P443
[2]  
BRUNDA MJ, 1994, J LEUKOCYTE BIOL, V55, P280
[3]   ANTITUMOR AND ANTIMETASTATIC ACTIVITY OF INTERLEUKIN-12 AGAINST MURINE TUMORS [J].
BRUNDA, MJ ;
LUISTRO, L ;
WARRIER, RR ;
WRIGHT, RB ;
HUBBARD, BR ;
MURPHY, M ;
WOLF, SF ;
GATELY, MK .
JOURNAL OF EXPERIMENTAL MEDICINE, 1993, 178 (04) :1223-1230
[4]   Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma [J].
Caruso, M ;
PhamNguyen, K ;
Kwong, YL ;
Xu, BS ;
Kosai, KI ;
Finegold, M ;
Woo, SLC ;
Chen, SH .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (21) :11302-11306
[5]  
COHEN J, 1995, SCIENCE, V270, P908
[6]   Interleukin-12 in anti-tumor immunity and immunotherapy [J].
Colombo, MP ;
Trinchieri, G .
CYTOKINE & GROWTH FACTOR REVIEWS, 2002, 13 (02) :155-168
[7]   Requirement for V(alpha)14 NKT cells in IL-12-mediated rejection of tumors [J].
Cui, JQ ;
Shin, T ;
Kawano, T ;
Sato, H ;
Kondo, E ;
Toura, I ;
Kaneko, Y ;
Koseki, H ;
Kanno, M ;
Taniguchi, M .
SCIENCE, 1997, 278 (5343) :1623-1626
[8]   Adenovirus-mediated intralesional interferon-γ gene transfer induces tumor regressions in cutaneous lymphomas [J].
Dummer, R ;
Hassel, JC ;
Fellenberg, F ;
Eichmüller, S ;
Maier, T ;
Slos, P ;
Acres, B ;
Bleuzen, P ;
Bataille, V ;
Squiban, P ;
Burg, G ;
Urosevic, M .
BLOOD, 2004, 104 (06) :1631-1638
[9]   Antitumor and antimetastatic effects of interleukin 12 [J].
Fujiwara, H ;
Hamaoka, T .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1996, 38 :S22-S26
[10]   Synergistic suppressive effect of double transfection of tumor necrosis factor-α and interleukin 12 genes on tumorigenicity of Meth-A cells [J].
Fujiwara, H ;
Yamauchi, N ;
Sato, Y ;
Sasaki, K ;
Takahashi, M ;
Okamoto, T ;
Sato, T ;
Iyama, S ;
Koshita, Y ;
Hirayama, M ;
Yamagishi, H ;
Niitsu, Y .
JAPANESE JOURNAL OF CANCER RESEARCH, 2000, 91 (12) :1296-1302